147 related articles for article (PubMed ID: 30632546)
1. Trastuzumab gold-conjugates: synthetic approach and in vitro evaluation of anticancer activities in breast cancer cell lines.
Curado N; Dewaele-Le Roi G; Poty S; Lewis JS; Contel M
Chem Commun (Camb); 2019 Jan; 55(10):1394-1397. PubMed ID: 30632546
[TBL] [Abstract][Full Text] [Related]
2. Local Radiation Treatment of HER2-Positive Breast Cancer Using Trastuzumab-Modified Gold Nanoparticles Labeled with
Cai Z; Yook S; Lu Y; Bergstrom D; Winnik MA; Pignol JP; Reilly RM
Pharm Res; 2017 Mar; 34(3):579-590. PubMed ID: 27987070
[TBL] [Abstract][Full Text] [Related]
3. Impact of cathepsin B-sensitive triggers and hydrophilic linkers on in vitro efficacy of novel site-specific antibody-drug conjugates.
Bryden F; Martin C; Letast S; Lles E; Viéitez-Villemin I; Rousseau A; Colas C; Brachet-Botineau M; Allard-Vannier E; Larbouret C; Viaud-Massuard MC; Joubert N
Org Biomol Chem; 2018 Mar; 16(11):1882-1889. PubMed ID: 29473076
[TBL] [Abstract][Full Text] [Related]
4. Multicomponent Conjugates of Anticancer Drugs and Monoclonal Antibody with PAMAM Dendrimers to Increase Efficacy of HER-2 Positive Breast Cancer Therapy.
Marcinkowska M; Stanczyk M; Janaszewska A; Sobierajska E; Chworos A; Klajnert-Maculewicz B
Pharm Res; 2019 Sep; 36(11):154. PubMed ID: 31482205
[TBL] [Abstract][Full Text] [Related]
5. An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro.
Bartusik-Aebisher D; Chrzanowski G; Bober Z; Aebisher D
Biomed Pharmacother; 2021 Jan; 133():111053. PubMed ID: 33378959
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of antibody-drug conjugates acting on HER2-positive cancer cells.
Chiang ZC; Chiu YK; Lee CC; Hsu NS; Tsou YL; Chen HS; Hsu HR; Yang TJ; Yang AS; Wang AH
PLoS One; 2020; 15(9):e0239813. PubMed ID: 32986768
[TBL] [Abstract][Full Text] [Related]
7. Multivalent exposure of trastuzumab on iron oxide nanoparticles improves antitumor potential and reduces resistance in HER2-positive breast cancer cells.
Truffi M; Colombo M; Sorrentino L; Pandolfi L; Mazzucchelli S; Pappalardo F; Pacini C; Allevi R; Bonizzi A; Corsi F; Prosperi D
Sci Rep; 2018 Apr; 8(1):6563. PubMed ID: 29700387
[TBL] [Abstract][Full Text] [Related]
8. Plant-Derived Anti-Human Epidermal Growth Factor Receptor 2 Antibody Suppresses Trastuzumab-Resistant Breast Cancer with Enhanced Nanoscale Binding.
Park C; Kim K; Kim Y; Zhu R; Hain L; Seferovic H; Kim MH; Woo HJ; Hwang H; Lee SH; Kim S; Lee JE; Hinterdorfer P; Ko K; Park S; Oh YJ
ACS Nano; 2024 Jun; 18(25):16126-16140. PubMed ID: 38764224
[TBL] [Abstract][Full Text] [Related]
9. Site-Specific Conjugation of Auristatins onto Engineered scFv Using Second Generation Maleimide to Target HER2-positive Breast Cancer in Vitro.
Aubrey N; Allard-Vannier E; Martin C; Bryden F; Letast S; Colas C; Lakhrif Z; Collinet N; Dimier-Poisson I; Chourpa I; Viaud-Massuard MC; Joubert N
Bioconjug Chem; 2018 Nov; 29(11):3516-3521. PubMed ID: 30352511
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab-monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2-positive human breast cancer.
Abdollahpour-Alitappeh M; Lotfinia M; Bagheri N; Sineh Sepehr K; Habibi-Anbouhi M; Kobarfard F; Balalaie S; Foroumadi A; Abbaszadeh-Goudarzi G; Abbaszadeh-Goudarzi K; Abolhassani M
J Cell Physiol; 2019 Mar; 234(3):2693-2704. PubMed ID: 30246298
[TBL] [Abstract][Full Text] [Related]
11. Loss of ARID1A Activates ANXA1, which Serves as a Predictive Biomarker for Trastuzumab Resistance.
Berns K; Sonnenblick A; Gennissen A; Brohée S; Hijmans EM; Evers B; Fumagalli D; Desmedt C; Loibl S; Denkert C; Neven P; Guo W; Zhang F; Knijnenburg TA; Bosse T; van der Heijden MS; Hindriksen S; Nijkamp W; Wessels LF; Joensuu H; Mills GB; Beijersbergen RL; Sotiriou C; Bernards R
Clin Cancer Res; 2016 Nov; 22(21):5238-5248. PubMed ID: 27172896
[TBL] [Abstract][Full Text] [Related]
12. Functionalized immunostimulating complexes with protein A via lipid vinyl sulfones to deliver cancer drugs to trastuzumab-resistant HER2-overexpressing breast cancer cells.
Rodríguez-Serrano F; Mut-Salud N; Cruz-Bustos T; Gomez-Samblas M; Carrasco E; Garrido JM; López-Jaramillo FJ; Santoyo-Gonzalez F; Osuna A
Int J Nanomedicine; 2016; 11():4777-4785. PubMed ID: 27698563
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity of Selenium Immunoconjugates against Triple Negative Breast Cancer Cells.
Khandelwal S; Boylan M; Spallholz JE; Gollahon L
Int J Mol Sci; 2018 Oct; 19(11):. PubMed ID: 30373175
[TBL] [Abstract][Full Text] [Related]
14. Novel trastuzumab-DM1 conjugate: Synthesis and bio-evaluation.
Abedi M; Cohan RA; Mahboudi F; Faramarzi MA; Fazel R; Damavandi N; Ardestani MS; Davami F
J Cell Physiol; 2019 Aug; 234(10):18206-18213. PubMed ID: 30854662
[TBL] [Abstract][Full Text] [Related]
15. Development and evaluation of β-galactosidase-sensitive antibody-drug conjugates.
Kolodych S; Michel C; Delacroix S; Koniev O; Ehkirch A; Eberova J; Cianférani S; Renoux B; Krezel W; Poinot P; Muller CD; Papot S; Wagner A
Eur J Med Chem; 2017 Dec; 142():376-382. PubMed ID: 28818506
[TBL] [Abstract][Full Text] [Related]
16. Impact of Site-Specific Conjugation of ScFv to Multifunctional Nanomedicines Using Second Generation Maleimide.
Hervé-Aubert K; Allard-Vannier E; Joubert N; Lakhrif Z; Alric C; Martin C; Viaud-Massuard MC; Dimier-Poisson I; Aubrey N; Chourpa I
Bioconjug Chem; 2018 May; 29(5):1553-1559. PubMed ID: 29553717
[TBL] [Abstract][Full Text] [Related]
17. Single molecule localization microscopy coupled with touch preparation for the quantification of trastuzumab-bound HER2.
Tobin SJ; Wakefield DL; Jones V; Liu X; Schmolze D; Jovanović-Talisman T
Sci Rep; 2018 Oct; 8(1):15154. PubMed ID: 30310083
[TBL] [Abstract][Full Text] [Related]
18. Phosphorylated HER3 and FITC-labeled trastuzumab immunohistochemistry in patients with HER2-positive breast cancer treated with adjuvant trastuzumab.
Kanomata N; Kurebayashi J; Moriya T
Med Mol Morphol; 2019 Jun; 52(2):106-113. PubMed ID: 30317526
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound Microbubbles Mediated Sonosensitizer and Antibody Co-delivery for Highly Efficient Synergistic Therapy on HER2-Positive Gastric Cancer.
Sun L; Zhang J; Xu M; Zhang L; Tang Q; Chen J; Gong M; Sun S; Ge H; Wang S; Liang X; Cui L
ACS Appl Mater Interfaces; 2022 Jan; 14(1):452-463. PubMed ID: 34961307
[TBL] [Abstract][Full Text] [Related]
20. Antibodies as Carrier Molecules: Encapsulating Anti-Inflammatory Drugs inside Herceptine.
Cerón-Carrasco JP; Pérez-Sánchez H; Zúñiga J; Requena A
J Phys Chem B; 2018 Feb; 122(7):2064-2072. PubMed ID: 29377693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
